FNFlor Navarro

Flor Navarro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Flor Navarro has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Stephanie K. Watkins

    Department of Surgery, Oncology Research Institute, Loyola University Chicago, Maywood, IL, USA

    5 shared publications
  • Juan José Lasarte

    Cancer Center Clinica Universidad de Navarra, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain

    3 shared publications
  • Marta Gorraiz

    Immunology and Immunotherapy Program, Center for Applied Medical Research, Cancer Center University of Navarra, Navarra Institute for Health Research, CIBERONC, Pamplona, Spain

    3 shared publications
  • Matthew G. Thompson

    Department of Surgery, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 S. 1st Ave. Building 112, Maywood, IL, 60153, USA

    3 shared publications
  • Noelia Casares

    Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain

    3 shared publications
  • Teresa Lozano

    Cancer Center Clinica Universidad de Navarra, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain

    3 shared publications

Latest Publications

  • Top Cited Papers
    Open Access

    Reprogramming glutamine metabolism enhances BCMA -CAR T-cell fitness and therapeutic efficacy in multiple myeloma

    by Flor Navarro, Teresa Lozano, Andrea Fuentes-García, Inés Sánchez-Moreno, Marta Larrayoz, Pedro Justicia, Beatriz Perucha, Maialen Martinez-Tabar, Rebeca Martinez-Turrillas, Noelia Casares, et al.

    Glutamine dependence of cancer cells reduces local glutamine availability, which hinders antitumor T-cell functionality and facilitates immune evasion. We thus speculated that glutamine deprivation might be limiting efficacy of chimeric antigen receptor (CAR) T-cell therapies in patients with cancer. We have seen that antigen-specific T cells are unable to proliferate or produce interferon gamma (IFN-γ) in response to antigen stimulation when glutamine concentration is limited. Using multiple myeloma (MM) as a glutamine-dependent disease model, we found that murine CAR T cells selectively targeting B-cell maturation antigen (Bcma) in MM cells were sensitive to glutamine deprivation. However, CAR T cells engineered to increase glutamine uptake by expression of the glutamine transporter Asct2 exhibited enhanced proliferation and responsiveness to antigen stimulation, increased production of IFN-γ, and heightened cytotoxic activity, even under conditions of low glutamine concentration. Mechanistically, Asct2 overexpression reprogrammed the metabolic fitness of CAR T cells by upregulating the mechanistic target of rapamycin complex 1 gene signature, modifying the solute carrier transporter repertoire, and improving both basal oxygen consumption rate and glycolytic function, thereby enhancing CAR T-cell persistence in vivo. Accordingly, expression of Asct2 increased the efficacy of Bcma-CAR T cells in syngeneic and genetically engineered mouse models of MM, which prolonged mouse survival. In patients, higher-level expression of ASCT2 by MM cells predicted poor outcome to combined immunotherapy and BCMA-CAR T-cell therapy. Our results indicate that reprogramming glutamine metabolism may enhance antitumor CAR T-cell functionality in MM. This approach may also be effective for other cancers that depend on glutamine as a key energy source and metabolic hallmark.


  • Open Access

    Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy

    by Flor Navarro, Noelia Casares, Celia Martín-Otal, Aritz Lasarte-Cía, Marta Gorraiz, Patricia Sarrión, Diana Llopiz, David Reparaz, Nerea Varo, Juan Roberto Rodriguez-Madoz, et al.

    The high metabolic activity and insufficient perfusion of tumors leads to the acidification of the tumor microenvironment (TME) that may inhibit the antitumor T cell activity. We found that pharmacological inhibition of the acid loader chloride/bicarbonate anion exchanger 2 (Ae2), with 4,4’-diisothiocyanatostilbene-2,2’-disulfonicacid (DIDS) enhancedCD4+ andCD8+ T cell function upon TCR activation in vitro, especially under low pH conditions. In vivo, DIDS administration delayed B16OVA tumor growth in immunocompetent mice as monotherapy or when combined with adoptive T cell transfer of OVA-specificT cells. Notably, genetic Ae2 silencing in OVA-specificT cells improvedCD4+/CD8+ T cell function in vitro as well as their antitumor activity in vivo. Similarly, genetic modification of OVA-specificT cells to overexpress Hvcn1, a selectiveH+ outward current mediator that prevents cell acidification, significantly improved T cell function in vitro, even at low pH conditions. The adoptive transfer of OVA-specificT cells overexpressing Hvcn1 exerted a better antitumor activity in B16OVA tumor-bearingmice. Hvcn1 overexpression also improved the antitumor activity of CAR T cells specific for Glypican 3 (GPC3) in mice bearing PM299L-GPC3tumors. Our results suggest that preventing intracellular acidification by regulating the expression of acidifier ion channels such as Ae2 or alkalinizer channels like Hvcn1 in tumor-specificlymphocytes enhances their antitumor response by making them more resistant to the acidic TME. Graphical abstract


  • Open Access

    Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma

    by Aritz Lasarte-Cia, Teresa Lozano, David Cano, Celia Martín-Otal, Flor Navarro, Marta Gorraiz, Noelia Casares, Isabel Vivas, Juan José Lasarte

    Background/Aim. Irreversible electroporation (IRE) showed promising results for small‐size tumors and very early cancers. However, further development is needed to evolve this procedure into a more efficient ablation technique for long‐term control of tumor growth. In this work, we show that it is possible to increase the antitumor efficiency of IRE by simmultaneously injecting c‐di‐GMP, a STING agonist, intratumorally. Materials and Methods. Intratumoral administration of c‐di‐GMP simultaneously to IRE was evaluated in murine models of melanona (B16.OVA) and hepatocellular carcinoma (PM299L). Results. The combined therapy increased the number of tumor‐infiltrating IFN‐γ/TNF‐α‐producing CD4 and CD8 T cells and delayed tumor growth, as compared to the effect observed in groups treated with c‐di‐GMP or IRE alone. Conclusion. These results can lead to the development of a new therapeutic strategy for the treatment of cancer patients refractory to other therapies.


  • Open Access

    Estrogen Regulation of T-Cell Function and Its Impact on the Tumor Microenvironment

    by Flor C. Navarro, Caroline Herrnreiter, Lauren Nowak, Stephanie K. Watkins

    Epidemiologic studies demonstrate significant gender-specific differences in immune system function. Males are more prone to infection and malignancies, while females are more vulnerable to autoimmune diseases. These differences are thought to be due to the action of gonadal hormones: Estrogen increases the inflammatory response and testosterone dampens it. More specifically, estrogen stimulation induces inflammatory cytokine production including interferon γ, interleukin (IL) 6, and tumor necrosis factor α, while testosterone induces IL-10, IL-4, and transforming growth factor β. More recent studies demonstrate threshold effects of estrogen stimulation on immune cell function: physiologic doses of estrogen (approximately 0.5 nmol/L) stimulate inflammatory cytokine production, but superphysiologic dosages (above 50 nmol/L) can result in decreased inflammatory cytokine production. This review reports findings concerning the impact of estrogen on CD8+cytotoxic T cells and the overall immune response in the tumor microenvironment. Variables examined include dosage of hormone, the diversity of immune cells involved, and the nature of the immune response in cancer. Collective review of these points may assist in future hypotheses and studies to determine sex-specific differences in immune responses that may be used as targets in disease prevention and treatment.


  • Open Access

    Estrogen Stimulation Differentially Impacts Human Male and Female Antigen-Specific T Cell Anti-Tumor Function and Polyfunctionality

    by Flor C. Navarro, Stephanie K. Watkins

    Sex-specific differences exist in innate and adaptive immune responses and are mediated by hormone signaling. Estrogen is able to differentially modulate the development and differentiation of immune cells, including T cells. However, the effect of estrogen on T cell function, especially at concentrations other than physiological, remains controversial and incompletely understood. Immunotherapy is one of the most promising cancer treatments to date with a high probability of future enhancements. The adoptive transfer of genetically modified T cells can mediate tumor regression but there are still many hurdles to enhancing the proficiency of this treatment. This study demonstrates for the first time that one major aspect to consider for designing potent immunotherapies for cancer is the impact of the patient's sex. Herein, using two different Ag-specific T cell groups, we investigated the effect of sex and estrogen in antitumor effector responses, T helper cytokine secretion, and, importantly, on T cell whole polyfunctionality important for memory T cell development and survival. Major differences were observed in T cell function and polyfunctionality between sexes and on E2 treatment. The findings of this study may be critical to understand the results of immunotherapy on different patients and for the enhancement of immunotherapy for cancer.


  • FOXO3, estrogen receptor alpha, and androgen receptor impact tumor growth rate and infiltration of dendritic cell subsets differentially between male and female mice

    by Matthew G. Thompson, Daniel S. Peiffer, Michelle Larson, Flor Navarro, Stephanie K. Watkins

    Tumors evade immune recognition and destruction in many ways including the creation of an immune-suppressive tumor microenvironment (TME). Dendritic cells (DC) that infiltrate the TME are tolerogenic, and suppress effector T cells and anti-tumor activity. Previous reports demonstrated that a key regulator of tolerance in DC is the transcription factor FOXO3. Gender disparity has been studied in cancer in relation to incidence, aggressiveness, and prognosis. Few studies have touched on the importance in relation to impact on the immune system. In the current study, we show that there are significant differences in tumor growth between males and females. Additionally, frequencies and the function of FOXO3 expressed by DC subsets that infiltrate tumors vary between genders. Our results show for the first time that DC FOXO3 expression and function is altered in females. In vitro results indicate that these differences may be the result of exposure to estrogen. These differences may be critical considerations for the enhancement of immunotherapy for cancer.


  • Open Access

    Alcohol exposure differentially effects anti-tumor immunity in females by altering dendritic cell function

    by Matthew G. Thompson, Flor Navarro, Lennox Chitsike, Luis Ramirez, Elizabeth J. Kovacs, Stephanie K. Watkins


  • Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma

    by Jared Klarquist, Kristen Tobin, Peyman Farhangi Oskuei, Steven W. Henning, Manuel F. Fernandez, Emilia R. Dellacecca, Flor C. Navarro, Jonathan M. Eby, Shilpak Chatterjee, Shikhar Mehrotra, et al.

    T regulatory cells (Treg) avert autoimmunity, but their increased levels in melanoma confer a poor prognosis. To explore the basis for Treg accumulation in melanoma, we evaluated chemokine expression in patients. A 5-fold increase was documented in the Treg chemoattractants CCL22 and CCL1 in melanoma-affected skin versus unaffected skin, as accompanied by infiltrating FoxP3+ T cells. In parallel, there was an approximately two-fold enhancement in expression of CCR4 in circulating Treg but not T effector cells. We hypothesized that redirecting Treg away from tumors might suppress autoimmune side effects caused by immune checkpoint therapeutics now used widely in the clinic. In assessing this hypothesis, we observed a marked increase in skin Treg in mice vaccinated with Ccl22, with repetitive vaccination sufficient to limit Treg accumulation and melanoma growth in the lungs of animals challenged by tumor cell injection, whether using a prevention or treatment protocol design. The observed change in Treg accumulation in this setting could not be explained by Treg conversion. Overall, our findings offered a preclinical proof of concept for the potential use of CCL22 delivered by local injection as a strategy to enhance the efficacious response to immune checkpoint therapy while suppressing its autoimmune side effects. Cancer Res; 76(21); 6230–40. ©2016 AACR.


  • Open Access

    033 CCL22 to divert regulatory T cells and control melanoma tumor growth

    by S. Henning, F. Navarro, P. Farhangi Oskuei, K. Tobin, M. Fernandez, J. Eby, J. Klarquist, S. Chatterjee, S. Mehrotra, J. Clark, et al.

  • Open Access

    FOXO3–NF-κB RelA Protein Complexes Reduce Proinflammatory Cell Signaling and Function

    by Matthew G. Thompson, Michelle Larson, Amy Vidrine, Kelly Barrios, Flor Navarro, Kaitlyn Meyers, Patricia Simms, Kushal Prajapati, Lennox Chitsike, Lance M. Hellman, et al.

    Tumor-associated myeloid cells, including dendritic cells (DCs) and macrophages, are immune suppressive. This study demonstrates a novel mechanism involving FOXO3 and NF-κB RelA that controls myeloid cell signaling and impacts their immune-suppressive nature. We find that FOXO3 binds NF-κB RelA in the cytosol, impacting both proteins by preventing FOXO3 degradation and preventing NF-κB RelA nuclear translocation. The location of protein–protein interaction was determined to be near the FOXO3 transactivation domain. In turn, NF-κB RelA activation was restored upon deletion of the same sequence in FOXO3 containing the DNA binding domain. We have identified for the first time, to our knowledge, a direct protein–protein interaction between FOXO3 and NF-κB RelA in tumor-associated DCs. These detailed biochemical interactions provide the foundation for future studies to use the FOXO3–NF-κB RelA interaction as a target to enhance tumor-associated DC function to support or enhance antitumor immunity.